Home » Stocks » ZOM

Zomedica Corp. (ZOM)

Stock Price: $0.0712 USD -0.0029 (-3.91%)
Updated Oct 28, 2020 11:03 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 40.16M
Revenue (ttm) n/a
Net Income (ttm) -13.46M
Shares Out 564.05M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $0.0712
Previous Close $0.0741
Change ($) -0.0029
Change (%) -3.91%
Day's Open 0.0720
Day's Range 0.0704 - 0.0730
Day's Volume 6,185,879
52-Week Range 0.0700 - 0.4990

More Stats

Market Cap 40.16M
Enterprise Value 12.51M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 564.05M
Float 538.58M
EPS (basic) -0.10
EPS (diluted) -0.11
FCF / Share -0.06
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 17.30M
Short Ratio 0.66
Short % of Float 3.21%
Beta -0.28
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.43
Revenue n/a
Operating Income -13.40M
Net Income -13.46M
Free Cash Flow -12.74M
Net Cash 27.65M
Net Cash / Share 0.05
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -39.47%
ROE -72.25%
ROIC -632.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $0.0712
Target: 0.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-19.79-16.65-8.08-5.73
Net Income-19.78-16.65-8.07-5.74
Shares Outstanding10693.4487.4080.16
Earnings Per Share-0.19-0.18-0.09-0.07
Operating Cash Flow-15.63-11.15-7.09-4.56
Capital Expenditures-0.16-0.62-0.17-0.23
Free Cash Flow-15.79-11.77-7.26-4.79
Cash & Equivalents0.511.943.453.23
Total Debt---0.01
Net Cash / Debt0.511.943.453.22
Book Value2.103.664.393.83
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zomedica Corp.
Country United States
Employees 28
CEO Robert Cohen

Stock Information

Ticker Symbol ZOM
Stock Exchange NYSE American
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSEAMERICAN: ZOM


Zomedica, a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.